Clinical Trial Update: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating a triple combination of Talimogene laherparepvec, Nivolumab, and Trabectedin for sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)
• Trabectedin (trabectedin)
• nivolumab (nivolumab)

Snippet

Sponsor: Sarcoma Oncology Research Center, LLC | Conditions: Sarcoma | Phase 2 | Status: RECRUITING